The adult epilepsy market is projected to grow to $17.8 billion by 2035, according to a new analysis from GlobalData. This figure marks a significant increase over current figures across the seven major markets, including the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. The report titled “Epilepsy (Adults): Disease Analysis Report and Forecast” suggests that the next decade will see substantial shifts in how the condition is treated and managed.
Drivers of Market Expansion
The primary engine for this expansion is a compound annual growth rate of 4.4 percent. GlobalData analysts attribute this rise to two main factors: a growing number of diagnosed prevalent cases and the introduction of 12 late-stage pipeline products. These emerging therapies are expected to reshape the sector, particularly as the industry moves toward therapies that address the fundamental mechanisms of the disease rather than just the symptoms.
Revenue projections depend on how well these drugs perform in real-world settings compared to the established generics. While the sales from these pipeline assets will become a major revenue source, the 7MM includes all markets previously listed. Analysts believe that while generics will remain a barrier, the sheer volume of diagnosed cases and the promise of these new treatments ensure that the market will continue to expand over the next decade.
Related: Emergency waits cut after fee reforms
Financial Outlook for Pipeline Assets
Financial projections indicate that these late-stage pipeline products will generate combined sales of approximately $5.4 billion in the 7MM by 2035. Of this total, disease-modifying therapies, or DMTs, will account for about a quarter of the revenue. This suggests that a significant portion of the market’s future value lies in treatments capable of altering the course of the disease itself, rather than simply suppressing the electrical storms that cause seizures.
Three of the 12 late-stage pipeline products are being developed as DMTs, aiming to address the underlying causes of epilepsy. The report notes that these therapies could signal a shift in the treatment paradigm. However, not all pipeline candidates share this goal. Some 12 pipeline therapies operate on synaptic mechanisms, and while demonstrating potential, are likely to encounter similar issues as currently marketed therapies.
Current Gaps in Treatment
Key opinion leaders (KOLs) interviewed for the analysis point out that significant unmet needs persist in the current medical setting. Despite the availability of a wide range of anti-seizure medications, the rates of achieving seizure freedom have remained relatively stable. This indicates that the existing pharmacological arsenal, while effective for some, fails to address the root causes of epilepsy for many patients.
Related: Blocked Users Get Sorry Message from Site
Jos Opdenakker, Neurology Analyst at GlobalData, noted that current marketed therapies focus on synaptic mechanisms. He stated that these drugs aim to either decrease brain excitation or increase inhibition. “These drugs are more symptomatic in their approach and do not address the underlying pathologies that produce seizures,” Opdenakker said. This reliance on symptom suppression rather than disease modification creates a ceiling on how well patients can be treated, regardless of how many different drugs are available.
Challenges and Barriers
Looking ahead, the market faces challenges that could temper its growth. Cheap generic drugs currently dominate the sector, creating a barrier to the adoption of newer, potentially more expensive therapies. However, analysts believe that the combination of rising diagnosed prevalence and the introduction of these late-stage products will be enough to drive the market forward through 2035.
Current treatments essentially manage symptoms, meaning patients often face a lifetime of daily medication without a guarantee of seizure freedom. If these new therapies successfully target the underlying pathophysiology, they could fundamentally change the prognosis for adults living with the condition, moving the standard from lifetime management to potential long-term remission, provided the safety profiles hold up in clinical practice.